Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

43.71USD
9 Dec 2019
Change (% chg)

$-0.37 (-0.84%)
Prev Close
$44.08
Open
$44.07
Day's High
$44.16
Day's Low
$43.66
Volume
1,903,499
Avg. Vol
1,574,060
52-wk High
$44.22
52-wk Low
$31.57

Latest Key Developments (Source: Significant Developments)

Boston Scientific - On Dec. 5, Company Entered $700 Million Credit Agreement
Friday, 6 Dec 2019 

Dec 5 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC - ON DEC 5, CO ENTERED INTO A $700 MILLION CREDIT AGREEMENT - SEC FILING.BOSTON SCIENTIFIC - CREDIT AGREEMENT PROVIDES FOR $700 MILLION 364 DAY TERM LOAN MATURING ON DEC 3, 2020.BOSTON SCIENTIFIC - PRINCIPAL AMOUNT OF 2019 TERM LOAN WILL BEAR INTEREST AT AN ANNUAL RATE OF LIBOR PLUS A MARGIN OF 0.65%.BOSTON SCIENTIFIC - TERM LOAN WILL BE USED TO REPAY REMAINING AMOUNTS OUTSTANDING UNDER 2-YEAR TRANCHE OF 2 TRANCHE $2 BILLION TERM LOAN CREDIT AGREEMENT.  Full Article

Boston Scientific's Unit And Ontario Municipal Employees Retirement System Entered Into Royalty Purchase Agreement
Tuesday, 26 Nov 2019 

Nov 26 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORP - ON NOV 26, UNIT OF CO AND ONTARIO MUNICIPAL EMPLOYEES RETIREMENT SYSTEM ENTERED INTO ROYALTY PURCHASE AGREEMENT.BOSTON SCIENTIFIC CORP - CO'S SUBSIDIARY SOLD TO OMERS 50% OF ROYALTIES PAYABLE IN RESPECT OF WORLDWIDE NET SALES OF ZYTIGA.BOSTON SCIENTIFIC CORP - PURCHASE PRICE FOR SUCH ROYALTY INTERESTS WAS U.S. $256 MILLION IN CASH.BOSTON SCIENTIFIC CORP - TRANSACTION IS EXPECTED TO HAVE NO IMPACT ON BOSTON SCIENTIFIC'S INCOME STATEMENT FOR 2019 AND THEREAFTER.BOSTON SCIENTIFIC CORP - CASH PROCEEDS FROM TRANSACTION ARE EXPECTED TO BE USED PRIMARILY TO PAY DOWN DEBT.BOSTON SCIENTIFIC CORP - TRANSACTION DOES NOT IMPACT BOSTON SCIENTIFIC'S FINANCIAL GUIDANCE FOR 2019 AS ROYALTY BUSINESS WAS DEEMED A PASSIVE BUSINESS.  Full Article

Biocardia - Filed Counterclaim In Federal Action Against Boston Scientific Parties, Surbhi Sarna
Wednesday, 6 Nov 2019 

Nov 6 (Reuters) - BioCardia Inc ::BIOCARDIA - ON OCT 31, FILED COUNTERCLAIM IN FEDERAL ACTION AGAINST BOSTON SCIENTIFIC PARTIES, SURBHI SARNA.BIOCARDIA INC - SEEKS IMPOSITION OF CONSTRUCTIVE TRUSTS BOTH ON PATENTS NAMING SURBHI SARNA AS AN INVENTOR.BIOCARDIA INC - SEEKS PROCEEDS RECEIVED FROM SALE OF NVISION TO BOSTON SCIENTIFIC, DAMAGES, INCLUDING UNJUST ENRICHMENT DAMAGES MEASURED BY PROCEEDS.  Full Article

Boston Scientific Reports Q3 GAAP Earnings Per Share Of $0.09
Wednesday, 23 Oct 2019 

Oct 23 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2019.Q3 GAAP EARNINGS PER SHARE $0.09.Q3 SALES $2.707 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.65 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.38 -- REFINITIV IBES DATA.SEES Q4 ADJUSTED EARNINGS PER SHARE $0.42 TO $0.45 EXCLUDING ITEMS.Q3 ADJUSTED EARNINGS PER SHARE $0.39.SEES REVENUE GROWTH FOR FULL YEAR 2019 TO BE IN A RANGE OF APPROXIMATELY 9 TO 9.5 PERCENT ON A REPORTED BASIS.SEES REVENUE GROWTH FOR FULL YEAR 2019 TO BE IN A RANGE OF APPROXIMATELY 7.5 PERCENT ON AN ORGANIC BASIS.BOSTON SCIENTIFIC - QTRLY CARDIOVASCULAR NET SALES $1,011 MILLION, UP 11.3%.SEES 2019 INCOME ON A GAAP BASIS IN A RANGE OF $0.72 TO $0.75 PER SHARE.SEES 2019 ADJUSTED EARNINGS IN A RANGE OF $1.55 TO $1.58 PER SHARE.Q4 EARNINGS PER SHARE VIEW $0.44 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.56, REVENUE VIEW $10.70 BILLION -- REFINITIV IBES DATA.  Full Article

Boston Scientific Closes Acquisition Of BTG Plc
Monday, 19 Aug 2019 

Aug 19 (Reuters) - BTG PLC ::BOSTON SCIENTIFIC CLOSES ACQUISITION OF BTG PLC.  Full Article

BTG Says High Court Of Justice In England And Wales Sanctions Scheme On Boston Scientific Deal
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - BTG Plc ::HIGH COURT OF JUSTICE IN ENGLAND AND WALES HAS TODAY MADE AN ORDER SANCTIONING SCHEME ON DEAL REGARDING BOSTON SCIENTIFIC.LAST DAY OF DEALING IN SHARES WILL BE 16 AUGUST 2019, ONCE SUSPENDED IT IS NOT EXPECTED THAT TRADING IN BTG SHARES WILL RECOMMENCE.  Full Article

Third Point LLC Takes Share Stake In Twilio, Cuts In Campbell Soup
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Third Point LLC::THIRD POINT LLC REPORTS SHARE STAKE OF 1.4 MILLION CLASS A SHARES IN PINTEREST INC - SEC FILING.THIRD POINT LLC TAKES SHARE STAKE OF 150,000 CLASS A SHARES IN TWILIO INC.THIRD POINT LLC CUTS SHARE STAKE IN CAMPBELL SOUP CO BY 11.9 PERCENT TO 18.5 MILLION SHARES.THIRD POINT LLC UPS SHARE STAKE IN MICROSOFT CORP BY 20.0 PERCENT TO 600,000 SHARES.THIRD POINT LLC UPS SHARE STAKE IN BOSTON SCIENTIFIC CORP BY 10.0 PERCENT TO 5.5 MILLION SHARES.THIRD POINT LLC UPS SHARE STAKE IN MARATHON PETROLEUM CORP BY 14.3 PERCENT TO 4.0 MILLION SHARES.  Full Article

Endologix Announces Exclusive Distributor Agreement With Boston Scientific For The Chinese Market
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES EXCLUSIVE DISTRIBUTOR AGREEMENT WITH BOSTON SCIENTIFIC FOR THE CHINESE MARKET.ENDOLOGIX INC - BOSTON SCIENTIFIC EXPECTS TO BEGIN SELLING PRODUCTS UPON LOCAL REGULATORY APPROVAL & SUBSEQUENT COMMERCIAL LAUNCH OF FIRST PRODUCT, ANTICIPATED IN 2021.  Full Article

Boston Scientific Responds To FDA's Guidance On Use Of Peripheral Paclitaxel Devices For Treatment Of PAD
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC CORPORATION - BOSTON SCIENTIFIC RESPONDS TO THE FDA’S GUIDANCE ON USE OF PERIPHERAL PACLITAXEL DEVICES FOR TREATMENT OF PAD.BOSTON SCIENTIFIC CORP - LOOK FORWARD TO COLLABORATING WITH FDA ON REVISED LABELING CHANGES, DATA COLLECTION REQUIREMENTS.  Full Article

Boston Scientific Says Sees Strong Uptake Of Eluvia In Japan
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Boston Scientific Corp ::CEO SAYS CO CONTINUES TO MAKE PROGRESS TO CLOSE BTG PLC <<>> DEAL IN AUGUST.CEO SAYS EXPECT SOME CONTINUED SOFTNESS IN 2019 IN SPINAL CORD STIMULATION MARKET.SAYS POST FDA MEETING ON PACLITAXEL DEVICES, PHYSICIANS CONTINUE TO ORDER ELUVIA IN LINE WITH INVESTOR DAY COMMENTARY.EXPECTS UPDATED SUMMARY AND GUIDANCE DOCUMENT ON PACLITAXEL DEVICES FROM FDA OVER NEXT FEW WEEKS - CONF CALL.SAYS ELUVIA REMAINS WELL POSITIONED IF FDA RECOMMENDS PACLITAXEL DEVICES ONLY FOR PATIENTS WITH HIGH RISK OF RESTENOSIS - CONF CALL.SAYS CONTINUE TO WORK TO RESOLVE MESH LITIGATION, WITH OVER 95% OF ALL KNOWN CLAIMS NOW SETTLED OR IN FINAL STAGES OF SETTLEMENT.SAYS ANTICIPATED COST TO LITIGATE HAS RISEN DUE TO VARIOUS JUDICIAL ORDERS RELATED TO TRANSVAGINAL MESH IMPLANTS.SAYS KNOWN CLAIM COUNT AND AMOUNT REQUIRED FOR MESH SETTLEMENT REMAIN UNCHANGED.SAYS ELUVIA WILL BE A "NICE GROWTH DRIVER" FOR CO IF FDA RECOMMENDATIONS ARE IN LINE WITH PANEL MEETING CONCLUSION.SAYS CO HAS CAPACITY TO MAKE TUCK-IN ACQUISITIONS IN 2019 - CONF CALL.SAYS DON'T SEE A SLOWDOWN IN SECOND HALF OF YEAR IN CHINA OR EMERGING MARKETS - CONF CALL.SAYS SEES STRONG UPTAKE OF ELUVIA IN JAPAN AS PACLITAXEL DEVICE SAFETY ISSUE DOESN'T SEEM TO BE CONCERNING IN JAPAN - CONF CALL.  Full Article

Stryker boosts bone implants with $4 billion Wright Medical buyout

Medical device maker Stryker Corp said on Monday it would buy smaller rival Wright Medical Group for about $4 billion in cash, expanding into the fast-growing business of implants for shoulders and wrists.